Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746546 | 0.90 | ALDH1A1 (0.41) | MAPK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25174478 | 0.84 | MAPK1 (0.41) | MAPK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29117284 | 0.83 | MAPK1 (0.37) | MAPK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29215638 | 0.82 | USP2 (0.43) | KDM4EATMCYP4F2CYP4A11 | |
| SCHEMBL3877084 | 0.80 | CYP2C19 (0.47) | MAPK1KDM4EALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL28278251 | 0.78 | CYP2C19 (0.50) | MAPK1KDM4EALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL28251465 | 0.77 | KDM4E (0.33) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL31231161 | 0.76 | CYP4F2 (0.43) | MAPK1KDM4ECYP4F2CYP4A11 | |
| SCHEMBL29215444 | 0.76 | CYP4F2 (0.43) | MAPK1KDM4ECYP4F2CYP4A11 | |
| SCHEMBL28501410 | 0.76 | PTGER2 (0.40) | MAPK1MEN1KMT2AALDH1A1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
| EP-1973914-A2 | TRANSFORMING GROWTH FACTOR MODULATORS | Biogen Idec MA Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007076086-A2 | TRICYCLIC SPIRO COMPOUNDS USEFUL AS TRANSFORMING GROWTH FACTOR MODULATORS | BIOGEN IDEC MA INC (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | ACVR1, TGFBR1, ACVRL1 | MAPK1 617/4885MEN1 1463/4885KMT2A 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.